Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
This means that NGF-induced hyperalgesia can occur in the absence of the p75 receptor and suggests that the trkA receptor is sufficient to mediate the acute noxious action of NGF.
|
9835221 |
1998 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
RGD |
Brain-derived neurotrophic factor increases in the uninjured dorsal root ganglion neurons in selective spinal nerve ligation model.
|
11425916 |
2001 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
RGD |
Blockade of NGF and trk receptors inhibits increased peripheral mechanical sensitivity accompanying cystitis in rats.
|
18448607 |
2008 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
CTD_human |
To confirm that the remaining, TrkA(+)/IB4(-), nociceptors are still functional, we evaluated if nerve growth factor (NGF) induced hyperalgesia.
|
20457222 |
2010 |
Hyperalgesia
|
0.600 |
Therapeutic
|
phenotype |
RGD |
Neural mobilization reverses behavioral and cellular changes that characterize neuropathic pain in rats.
|
22839415 |
2012 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Since that time, NGF has also been shown to play a key role in the generation of acute and chronic pain and in hyperalgesia in diverse pain states.
|
23157347 |
2013 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Here we performed long-term evaluation of allodynia and hyperalgesia in a CCI model, and evaluated the effects of NGF and SP on the peripheral and central nervous systems.
|
28685530 |
2017 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Hyperalgesia developed after NGF injection in the infrapatellar fat pad, but it was not facilitated by acid provocation.
|
27634419 |
2017 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Local pre-treatment with anti-NGF or K252a was effective to prevent ET-1 induced heat hyperalgesia.
|
28865353 |
2017 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
ZMIZ1 has previously been associated with several autoimmune diseases, and NGF plays a key role in the generation of pain and hyperalgesia and has been associated with migraine.
|
28447608 |
2017 |
Hyperalgesia
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
This study aimed to investigate the relationship between the dynamic expression of NGF in dorsal horn and dorsal root ganglion (DRG) of diabetic rats and hyperalgesia and allodynia in diabetic neuropathic pain.
|
28535564 |
2017 |
Hyperalgesia
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
Pressure stimulation, contact heat stimulation, hyperalgesia (pinprick stimulation) and allodynia (brush stimulation) to mechanical stimulation were performed in the area where capsaicin and NGF were injected.
|
29498480 |
2018 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Intraplantar injection of NGF<sup>R100W</sup> into adult rats induced neither TrkA-mediated thermal nor mechanical acute hyperalgesia, but retained the ability to induce chronic hyperalgesia based on agonism for TrkA signaling.
|
29483280 |
2018 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Nerve growth factor (NGF) injected into the human skin causes local hyperalgesia to mechanical and electrical stimuli lasting for weeks.
|
29140928 |
2018 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
This study utilized two established human models of cutaneous nociceptive sensitization to explore how pre-established inflammatory hyperalgesia (ultraviolet-B-irradiation; "UVB") and non-inflammatory neurotrophic pain sensitization (nerve growth factor; "NGF") alter sensitivity to chemical and mechanically evoked itch.
|
29406574 |
2018 |
Hyperalgesia
|
0.600 |
GeneticVariation
|
phenotype |
BEFREE |
Intramuscular injection of nerve growth factor (NGF) causes muscle hyperalgesia without immediate pain.
|
30513347 |
2019 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Nerve growth factor is an inflammatory mediator that induces long-lasting hyperalgesia, which can partially be attributed to nerve growth factor-induced sensitization of primary afferent nociceptors.
|
30387376 |
2019 |
Hyperalgesia
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
Therefore, this study investigated the effect of NGF on ASIC3 expression in the TNC and the role of NGF signaling in chemical dural stimulation-induced hyperalgesia.
|
30553789 |
2019 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Nerve growth factor (NGF) has been implicated in hyperalgesia by sensitising nociceptors.
|
31383364 |
2019 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Nerve growth factor-induced muscle hyperalgesia facilitates ischaemic contraction-evoked pain.
|
31314952 |
2019 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Development of hyperalgesia may be associated with an increase in NGF as well as increased inflammatory mediators.
|
31152170 |
2019 |
Hyperalgesia
|
0.600 |
GeneticVariation
|
phenotype |
BEFREE |
Local injection of nerve growth factor (3 µg/50 µl) or the TRPV1 agonist capsaicin (1 μg/50 μl), but not neurotrophin-3 injection (1 µg/50 µl), resulted in long-lasting facial heat hyperalgesia, which was both significantly reduced by previous neurotrophin-3 local treatment.
|
31577558 |
2020 |
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
A dipeptide mimetic of NGF loop 4, bis(N-succinyl-L-glutamyl-L-lysine) hexamethylenediamide (GK-2), developed at the Zakusov Research Institute of Pharmacology, has the NGF-like ability to activate TrkA receptors, but unlike NGF, GK-2 activates mainly the PI3K/AKT pathway associated with neuroprotection and has no effect on the MAPK cascade associated with hyperalgesia, the main side effect of NGF.
|
31720014 |
2020 |